Alnylam Pharmaceuticals, Inc., 10% Owner at Regulus Therapeutics Inc. ("RGLS"), sold 5,350 shares at $6.42 ($34K) on 2014-07-31, disclosed to the SEC on 2014-08-01.
Scheduled sale ($34k) by 10% Owner under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $6.60 | 1,000 | $7K | 19.4% |
| 2 | $6.42 | 1,750 | $11K | 33.1% |
| 3 | $6.21 | 2,600 | $16K | 47.5% |
| Total | $6.35 avg | 5,350 | $34K | 100% |
| Filing → |
| RGLS | SELL | 2014-10-24 | $1.6M | — | Filing → |
| RGLS | SELL | 2014-10-17 | $81K | — | Filing → |
| RGLS | SELL | 2014-10-10 | $66K | — | Filing → |